Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


The Impact of Clinical Trials in Tennessee


 
Sen. Mark Green, MD, discusses the importance of local clinical trials and biopharmaceutical research in Tennessee. Pictured (L-R) James and Josi Felts, Dr. Paul Newhouse, Dr. Jeffrey Conn, and Sen. Mark Green.

On Jan. 23, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 945 active clinical trials in the Tennessee. Additionally, the report said the life science industry supports 52,000 jobs and contributes $11.7 billion to the state's economy.

"Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in Tennessee," was released at an event held at the Cordell Hull Building, which featured a panel discussion by Vanderbilt University Medical Center biotech researchers, Tennessee State Senator Mark Green, MD, (R-22), and a local Alzheimer's disease patient and clinical trial participant.

"Clinical trials offer patients novel medical treatments while also allowing biopharma research organizations to innovate and grow," said Green, founder of Align MD. "Across the state - and particularly here in Nashville - the healthcare industry has had a profound impact on our economy."

In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations. In Tennessee, active trials are studying treatment options for more than 20 disease sites or types, with cancer trials leading the way by a large margin. Of the 945 open clinical trials involving the biopharmaceutical research industry, Vanderbilt is collaborating on more than 245 of them. In addition, the report cites Meharry Medical College, Sarah Cannon, Clinical Research Associates, Tennessee Clinical Research Center, Tennessee Oncology, Tennessee Retina, and all of the city's major hospitals and health systems as active participants in Nashville.

"Many top universities call Tennessee home and are centers of innovation," said Jeffrey Conn, PhD, director of the Vanderbilt Center for Neuroscience Drug Discovery. "Maintaining strong partnerships between medical universities and life science companies allows us to foster developments right here in Tennessee that can then help save lives far beyond our state lines."

On average, it takes approximately a decade for new medicines to go through the FDA approval process, and only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted more than 6,100 clinical trials in Tennessee.

The complete report is available online at NashvilleMedicalNews.com

WEB:

Research in Your Backyard Report

 
Share:

Related Articles:


Recent Articles

THA Honors 26 Hospital Leaders at Annual Meeting

Tennessee Hospital Association (THA) today honored 26 hospital administrators, employees and volunteers during its 2018 Annual Meeting. The awards luncheon was held at the Franklin Marriott Cool Springs.

Read More

AMA Announces Playbook to Successfully Adopt Digital Health

Best practices based on lessons learned from multiple sources are combined into an authoritative resource

Read More

PYA Publishes New White Paper: "Urgent Care Centers: A Solution to Overuse of Hospital Emergency Rooms--Valuation Considerations"

PYA, a national management consulting and accounting firm, recently released a white paper that offers insights on valuation considerations related to urgent care centers.

Read More

Corker: PEPFAR Reauthorization Bill Passes Committee, Extends Successful U.S. Program to Combat HIV/AIDS

U.S. Senator Bob Corker (R-Tenn.), chairman of the Senate Foreign Relations Committee, today praised committee passage of legislation he authored with U.S. Senator Bob Menendez (D-N.J.) to extend the President's Emergency Plan for AIDS Relief (PEPFAR) for another five years.

Read More

TDH Issues Public Health Advisory On Cannabis

Evidence, Known Harms Increase Concerns about Risks to Health

Read More

HHS Secretary Addresses Nashville Health Care Council Audience

On Thursday, Sept. 27, Health and Human Services Secretary Alex M. Azar II flew to Nashville to share thoughts and updates on healthcare coverage in America during a Nashville Health Care Council Event held at Lipscomb University.

Read More

The War Against Opioids in Pain Management

Awareness, innovative therapies are effective tools to manage pain and ward against addiction.

Read More

Designed to Disinfect: The Relation Between Interior Design & Infection Control

About one in 25 patients in America has at least one healthcare-associated infection (HAI) on any given day, according to the most recent statistics from the Centers for Disease Control and Prevention.

Read More

Physician Spotlight: Changing Minds

Acadia Healthcare CMO Michael Genovese, MD, JD, tackles misconceptions around mental health and addiction.

Read More

Addressing the Gap Between Need & Access in Treating Addiction

Need far outstrips capacity when it comes to treating substance abuse disorders. American Addiction Centers CMO Dr. Lawrence Weinstein discusses barriers to care and possible solutions.

Read More

Email Print
 
 

 

 


Tags:
Biopharmaceutical Research, Clinical Trials, Jeffrey Conn, Life Sciences, Mark Green, Pharmaceutical Research and Manufacturers of America, Pharmaceuticals, PhRMA, Research in Your Backyard, Vanderbilt
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: